

## 2020-2021 ECCO Annual Disclosure of Potential Conflict of Interest

**Surname (Last Name): Colombel**

**Given Name (First Name): Jean-Frédéric**

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'21 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'21 presentations, the 2020-2021 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
  - I have no potential conflict of interest to disclose
  - I have potential conflict of interest to disclose
- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
  - Grant
  - Personal Fees
  - Non-financial support
  - Other

### **Disclosures statement based on answers received:**

**Grant:|AbbVie, Janssen Pharmaceuticals and Takeda| |Other:|Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Geneva, Genentech, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Ipsen, Imedex, Immunic, Imtbio, Medimmune, Merck, Novartis, O Mass, Ostuka, Pfizer, SERENE CD, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit. |**